RNS Number : 2690L MaxCyte, Inc. 07 November 2024 MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance ROCKVILLE, MD , November 7, 2024 - MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 2188L MaxCyte, Inc. 06 November 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , November 6, 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies
RNS Number : 8533K MaxCyte, Inc. 04 November 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights ROCKVILLE, MD , November 4, 2024 : MaxCyte Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance
RNS Number : 4096K MaxCyte, Inc. 31 October 2024 MaxCyte to Participate in Two Upcoming Investor Conferences Rockville, MD , Oct. 31, 2024 - MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
RNS Number : 3072K MaxCyte, Inc. 31 October 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , October 31, 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 7726I MaxCyte, Inc. 18 October 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Grant of Options and Restricted Stock Units ROCKVILLE, MD , October 18, 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 2348I MaxCyte, Inc. 15 October 2024 MaxCyte Appoints Cynthia Collins to its Board of Directors Rockville, MD , Oct. 15, 2024 - MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
RNS Number : 8857H MaxCyte, Inc. 11 October 2024 MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 ROCKVILLE, MD , October 11, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT ), a leading, cell-engineering focused company providing enabling platform technologies to
RNS Number : 7240H MaxCyte, Inc. 10 October 2024 MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer Rockville, MD , Oct. 10, 2024 - MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance
RNS Number : 8297G MaxCyte, Inc. 03 October 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , October 3, 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
